MA46361A - Traitement du cancer de la prostate - Google Patents
Traitement du cancer de la prostateInfo
- Publication number
- MA46361A MA46361A MA046361A MA46361A MA46361A MA 46361 A MA46361 A MA 46361A MA 046361 A MA046361 A MA 046361A MA 46361 A MA46361 A MA 46361A MA 46361 A MA46361 A MA 46361A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- prostate cancer
- prostate
- cancer
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402004P | 2016-09-30 | 2016-09-30 | |
| US201662402150P | 2016-09-30 | 2016-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46361A true MA46361A (fr) | 2021-03-31 |
Family
ID=60915459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046361A MA46361A (fr) | 2016-09-30 | 2017-09-29 | Traitement du cancer de la prostate |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10449191B2 (fr) |
| EP (1) | EP3518932A2 (fr) |
| JP (1) | JP7062673B2 (fr) |
| CN (1) | CN110248661A (fr) |
| AU (2) | AU2017334035B2 (fr) |
| BR (1) | BR112019006228A2 (fr) |
| CA (1) | CA3038875A1 (fr) |
| IL (3) | IL308528A (fr) |
| MA (1) | MA46361A (fr) |
| MX (2) | MX2019003733A (fr) |
| NZ (1) | NZ752918A (fr) |
| WO (1) | WO2018060463A2 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2912929T3 (es) | 2016-09-30 | 2022-05-30 | Myovant Sciences Gmbh | Métodos de tratamiento de fibromas uterinos y endometriosis |
| AU2017334035B2 (en) * | 2016-09-30 | 2022-11-24 | Sumitomo Pharma Switzerland Gmbh | Treatment of prostate cancer |
| CN110194776B (zh) * | 2019-06-27 | 2021-05-28 | 四川伊诺达博医药科技有限公司 | 一种瑞卢戈利的合成方法 |
| JP2022551316A (ja) * | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
| WO2021069700A1 (fr) * | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Formes cristallines solvatées de n-(4-(1-(2,6-difluorobenzyle)-5- ((diméthylamino)méthyle)-3-(6-méthoxy-3-pyridazinyle)-2,4-dioxo -1,2,3,4-tétrahydrothiéno[2,3-d]pyrimidine-6-yl) phényle)-n'-méthoxyurée |
| MX2022015003A (es) | 2020-05-29 | 2023-03-03 | Myovant Sciences Gmbh | Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina. |
| EP4232164A1 (fr) * | 2020-10-20 | 2023-08-30 | Baylor College of Medicine | Marqueurs métaboliques multiplexes dans le plasma pour la détection précoce du cancer de la prostate chez les afro-américains |
| EP4243829A1 (fr) | 2020-11-11 | 2023-09-20 | Myovant Sciences GmbH | Méthodes d'administration du rélugolix |
| WO2023066941A1 (fr) | 2021-10-18 | 2023-04-27 | Myovant Sciences Gmbh | Forme cristalline d'un solvate d'éthanol de n-(4-(1-(2,6-difluorobenzyle)-5-((diméthylamino)méthyle)-3-(6-méthoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tétrahydrothiéno[2,3-d]pyrimidin-6-yl)phényle)-n'-méthoxyurée |
| WO2023152611A1 (fr) * | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide et relugolix pour le traitement du cancer de la prostate |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2233284C2 (ru) | 1999-03-24 | 2004-07-27 | Такеда Кемикал Индастриз, Лтд. | Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона |
| TWI225863B (en) | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| US6849738B2 (en) | 2000-02-29 | 2005-02-01 | Takeda Chemical Industries, Ltd. | Processes for the production of thienopyrimidine derivatives |
| US7569570B2 (en) | 2002-01-30 | 2009-08-04 | Takeda Pharmaceutical Company Limited | Thienopyrimidines, process for preparing the same and use thereof |
| NZ541772A (en) | 2003-01-29 | 2009-10-30 | Takeda Pharmaceutical | Thienopyrimidine compounds and use thereof |
| MXPA06000297A (es) | 2003-07-07 | 2006-03-28 | Neurocrine Biosciences Inc | Derivados de pirimidina-2,4-diona como antagonistas del receptor de la hormona de liberacion de gonadotropina. |
| BRPI0613643A2 (pt) | 2005-07-22 | 2012-11-06 | Takeda Pharmaceutical | inibidor de ovulação prematura, método de inibir ovulação prematura e uso de um composto |
| PE20090044A1 (es) | 2007-04-06 | 2009-01-23 | Neurocrine Biosciences Inc | Antagonistas del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos |
| WO2009062087A1 (fr) | 2007-11-07 | 2009-05-14 | Neurocrine Biosciences, Inc. | Procédés de préparation de dérivés d'uracile |
| EP2329823A4 (fr) | 2008-09-03 | 2013-04-03 | Takeda Pharmaceutical | Procédé pour améliorer la capacité d'une préparation à être absorbée et préparation dont la capacité à être absorbée est améliorée |
| PL2900675T3 (pl) | 2012-09-28 | 2019-08-30 | Takeda Pharmaceutical Company Limited | Sposób wytwarzania pochodnej tienopirymidyny |
| CN107249590A (zh) | 2015-02-26 | 2017-10-13 | 武田药品工业株式会社 | 固体制剂 |
| US20180044977A1 (en) | 2016-08-12 | 2018-02-15 | Raynor Mfg. Co. | Rolling door construction for controlling air leakage |
| AU2017334035B2 (en) | 2016-09-30 | 2022-11-24 | Sumitomo Pharma Switzerland Gmbh | Treatment of prostate cancer |
| ES2912929T3 (es) | 2016-09-30 | 2022-05-30 | Myovant Sciences Gmbh | Métodos de tratamiento de fibromas uterinos y endometriosis |
-
2017
- 2017-09-29 AU AU2017334035A patent/AU2017334035B2/en active Active
- 2017-09-29 NZ NZ752918A patent/NZ752918A/en unknown
- 2017-09-29 BR BR112019006228A patent/BR112019006228A2/pt unknown
- 2017-09-29 IL IL308528A patent/IL308528A/en unknown
- 2017-09-29 WO PCT/EP2017/074849 patent/WO2018060463A2/fr active Application Filing
- 2017-09-29 JP JP2019538720A patent/JP7062673B2/ja active Active
- 2017-09-29 IL IL300071A patent/IL300071A/en unknown
- 2017-09-29 EP EP17823017.3A patent/EP3518932A2/fr active Pending
- 2017-09-29 CN CN201780072970.4A patent/CN110248661A/zh active Pending
- 2017-09-29 MX MX2019003733A patent/MX2019003733A/es unknown
- 2017-09-29 MA MA046361A patent/MA46361A/fr unknown
- 2017-09-29 CA CA3038875A patent/CA3038875A1/fr active Pending
-
2019
- 2019-03-28 IL IL265697A patent/IL265697B2/en unknown
- 2019-03-29 US US16/369,729 patent/US10449191B2/en active Active
- 2019-03-29 MX MX2023001468A patent/MX2023001468A/es unknown
- 2019-09-06 US US16/563,161 patent/US10786501B2/en active Active
-
2020
- 2020-08-20 US US16/998,900 patent/US11583526B2/en active Active
-
2022
- 2022-07-15 US US17/866,203 patent/US20220401443A1/en active Pending
-
2023
- 2023-02-22 AU AU2023201047A patent/AU2023201047A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL265697A (en) | 2019-05-30 |
| EP3518932A2 (fr) | 2019-08-07 |
| US20190224196A1 (en) | 2019-07-25 |
| JP7062673B2 (ja) | 2022-05-06 |
| CA3038875A1 (fr) | 2018-04-05 |
| US20220401443A1 (en) | 2022-12-22 |
| WO2018060463A2 (fr) | 2018-04-05 |
| WO2018060463A3 (fr) | 2018-05-11 |
| US10449191B2 (en) | 2019-10-22 |
| MX2019003733A (es) | 2019-09-26 |
| MX2023001468A (es) | 2023-03-03 |
| CN110248661A (zh) | 2019-09-17 |
| AU2023201047A1 (en) | 2023-03-23 |
| JP2019529574A (ja) | 2019-10-17 |
| US11583526B2 (en) | 2023-02-21 |
| IL300071A (en) | 2023-03-01 |
| US10786501B2 (en) | 2020-09-29 |
| BR112019006228A2 (pt) | 2019-06-18 |
| US20210205303A1 (en) | 2021-07-08 |
| IL265697B2 (en) | 2023-07-01 |
| AU2017334035A1 (en) | 2019-05-16 |
| IL265697B1 (en) | 2023-03-01 |
| AU2017334035B2 (en) | 2022-11-24 |
| NZ752918A (en) | 2022-09-30 |
| IL308528A (en) | 2024-01-01 |
| US20200129507A1 (en) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46361A (fr) | Traitement du cancer de la prostate | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA43374A (fr) | Méthodes de traitement de tumeurs malignes | |
| HK1258098A1 (zh) | 治療癌症的方法 | |
| MA50056A (fr) | Procédés de traitement de tumeur | |
| MA47501A (fr) | Dérivé de di-nucléotides cycliques pour le traitement du cancer | |
| MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
| MA43190A (fr) | Traitement de la dyslipidémie mixte | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA47408A (fr) | Traitement du cancer | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| DK3458052T3 (da) | Kombinationsbehandling af cancer | |
| MA45780A (fr) | Méthodes de traitement du cancer de la prostate | |
| MA44612A (fr) | Méthodes de traitement de cancers pédiatriques | |
| MA45675A (fr) | Méthodes et compositions permettant le traitement du cancer | |
| IL262342A (en) | Cancer treatment methods | |
| MA49059A (fr) | Traitement des cancers positifs à her2 | |
| MA52627A (fr) | Traitement du cancer | |
| MA42930A (fr) | Traitement de maladies neurodégénératives | |
| DK3525774T3 (da) | Lasofoxifen behandling af er+ brystcancer | |
| IL263835A (en) | Exosome-guided treatment of cancer | |
| DK3576740T3 (da) | Cancerbehandling | |
| MA42444A (fr) | Traitement du prurit | |
| DK3407909T3 (da) | Cancerbehandling |